/
Unless the context otherwise requires, for purposes of this section, the terms we, us, our, our Company, the Company or Senti refer to Senti Biosciences, Inc. and its subsidiaries. Overview We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases.
The business is unprofitable at the operating level (-312631.82% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
ROIC dropped from -58.85% to -115.89%, capital efficiency is deteriorating. Negative free cash flow of -$44M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$22K
Net Income (TTM)
-$52M
▼ -16.4% YoY
Op. Margin
-312631.82%
ROIC
-119.76%
▼ -57.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$37M
▼ -5.4% YoY
Op. Cash Flow (TTM)
-$37M
▼ -4.9% YoY
Net Debt
$10M
Cash & Equiv.
$9M
3Y CAGR: -82.7%
Continue Research